[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100437076":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":33,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Case",null,"Patients with cerebral hypoxia victims of ischaemic stroke, acute parenchymal haemorrhage or subarachnoid haemorrhage",[13],"Other: Blood sampling",{"label":15,"type":10,"description":16,"interventionNames":17},"Control","Patients without cerebral hypoxia",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Blood sampling","Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion",[9,15],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"François DELVOYE","CONTACT","0148036556","fdelvoye@for.paris",{"name":31,"role":27,"phone":28,"phoneExt":10,"email":32},"Amélie Yavchitz","fyavchitz@for.paris",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Hôpital Fondation Adolphe de Rothschild","RECRUITING","Paris","Île-de-France Region","75010","France","FR",{"type":43,"coordinates":44},"Point",[45,46],2.3488,48.85341,{"lat":46,"lon":45},[49],{"name":50,"role":27,"phone":51,"phoneExt":10,"email":52},"Amélie Yavchitz, MD","01 48 03 64 54","ayavchitz@for.paris",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100437076","thrombo-inflammation-biomarkers-trial-in-acute-cerebral-hypoxia-100437076",false,"NCT04971564","Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia","Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia. A Case-control Trial Nested in a Cohort","RADICAL","Inclusion Criteria:\n\n\\- For cases, admitted within the first 36 hours of an acute neurological symptom related to :\n\n* An ischaemic cerebrovascular accident (iCVA) eligible for a mechanical thrombectomy procedure,\n* A subarachnoid haemorrhage (SAH, all aetiologies) : patient presenting with at least a modified Fisher scale 3 or 4,\n* An intra-parenchymal haematoma (IPH) with greatest axis ≥ 20mm or with NIHSS on admission \\>4.\n\nOR\n\n* For control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (TIA) - based on thorough questioning of the patient on admission - and prior to imaging, with an ABCD2≥ 2 score.\n* Express consent to participate in the study.\n* Member or beneficiary of a social security.\n\nExclusion Criteria:\n\n* Pre-existing functional and\u002For cognitive disability\n* Patient under legal protection.\n* Pregnant or breastfeeding woman.\n* Patient with secondary haemorrhagic transformation.\n\nSecondary exclusion criteria :\n\n* Patients with an ischaemic lesion visible on imaging, unrelated to large vessel occlusion and therefore ineligible for mechanical thrombectomy.\n* Patients diagnosed with an acute non-vascular neurological pathology (migraine, epilepsy, etc.).\n* TIA patients presenting an abnormality on follow-up imaging 24-48 hours after the initial imaging.\n\nExcluded patients will be replaced.","ALL","18 Years",{"count":66,"type":67},200,"ESTIMATED","OBSERVATIONAL","The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.",[71,72],"Cerebral Hypoxia","Ischemic Stroke","2026-01-21",{"date":75,"type":76},"2026-01-22","ACTUAL",{"date":78,"type":76},"2024-03-19",{"date":80,"type":67},"2026-06-22",{"name":5,"class":6},1]